Patents Examined by Jeanine A. Goldberg
  • Patent number: 10619218
    Abstract: The invention pertains to analyzing the levels of DNA methylation at specific genetic loci to detect specific body fluids, for example, vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, or blood or blood cells. Particularly, the levels of methylation of DNA at the genetic loci corresponding to SEQ ID NOs: 1, 6, 11, and 16 are used to detect vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, and blood or blood cells, respectively. The level of methylation at the specific loci can be determined by high-resolution melt analysis (HRM) or sequencing of the amplicons produced using specific primers designed to amplify the specific loci. Kits containing the primers and reagents for carrying out the methods disclosed herein are also provided.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 14, 2020
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Bruce McCord, Joana Antunes
  • Patent number: 10619208
    Abstract: The present invention relates to a novel procedure for evaluating the response of patients affected by Ataxia Talangiectasia (A-T) to glucocorticoids treatment. In particular, the procedure provides a step of qualitative and/or quantitative identification in the blood of said patients of the expression of a mRNA variant of the ATM (Ataxia-Talangiectasia-Mutated) gene produced by non-canonical splicing induced by glucocorticoid (GC). In fact, it was demonstrated that mRNA variant expression is present in the blood of patients who responded positively to treatment with GC.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 14, 2020
    Assignee: EryDel S.p.A.
    Inventors: Mauro Magnani, Sara Biagiotti, Michele Menotta
  • Patent number: 10612101
    Abstract: Methods for the rapid detection of the presence or absence of Mycoplasma genitalium (MG) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the target MG gene, along with kits are provided that are designed for the detection of MG.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 7, 2020
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Jody Harris, Kalyani Mangipudi
  • Patent number: 10604808
    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 31, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Yu-Kwan Tong, Chunming Ding
  • Patent number: 10597734
    Abstract: The application is related to novel signature sequences for diagnosis of Mycobacterium tuberculosis in clinical samples with 100% specificity and a very high degree of sensitivity.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: March 24, 2020
    Assignees: EUROPEAN MOLECULAR BIOLOGY LABORATORY, KUSUMA SCHOOL OF BIOLOGICAL SCIENCES INDIAN INSTITUTE OF TECHNOLOGY
    Inventors: Syed Asad Rahman, Javeed Ahmad, Nasreen Z Ehtesham, Seyed E Hasnain
  • Patent number: 10597733
    Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 24, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Exact Sciences Development Company, LLC
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney, Hatim T. Allawi
  • Patent number: 10590488
    Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Delphine Rolland, Bryan L. Betz, Nathanael G. Bailey, Thirunavukkarasu Velusamy, Megan Lim
  • Patent number: 10563263
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 18, 2020
    Assignee: Celera Corporation
    Inventor: Dov Shiffman
  • Patent number: 10557175
    Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: February 11, 2020
    Assignees: THE PROVOST, FELLOWS, SCHOLARS AND OTHER MEMBERS OF BOARD OF TRINITY COLLEGE DUBLIN, UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
    Inventors: Adrian Bracken, Fiona Lanigan, William Gallagher
  • Patent number: 10557170
    Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 11, 2020
    Assignee: Gendiag.exe, S.L.
    Inventors: Eduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo Fernandez
  • Patent number: 10550433
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 4, 2020
    Assignees: The Brigham and Women's Hospital, Inc., Celera Corporation
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Patent number: 10550430
    Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 4, 2020
    Assignees: BIONTECH DIAGNOSTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Michael Schäfer, Marta Magdalena Faryna, Tana Omokoko, Lisa Hebich, Petra Simon, Annett Reichardt, Özlem Öz
  • Patent number: 10533049
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: January 14, 2020
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 10526659
    Abstract: Biomarkers and methods related to microbiota for predicting the risk of a disease, particularly colorectal cancer (CRC), are described.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 7, 2020
    Assignees: BGI Shenzhen Co., Limited, BGI Shenzhen
    Inventors: Qiang Feng, Dongya Zhang, Longqing Tang, Jun Wang
  • Patent number: 10519228
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: December 31, 2019
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 10519503
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Hamid Azzedine, Alexis Brice, Giovanni Stevanin, Filippo Santorelli, Paola Denora
  • Patent number: 10519227
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: December 31, 2019
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 10513740
    Abstract: Primer pair, kit and method for detecting Anaplasma platys are disclosed. The primer pair includes a forward primer and a reverse primer, and the kit includes the primer pair and a probe. The forward primer has a sequence of SEQ ID NO: 1, the reverse primer has a sequence of SEQ ID NO: 2, and the probe has a sequence of SEQ ID NO: 3.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: December 24, 2019
    Assignee: DELTA ELECTRONICS INT'L (SINGAPORE) PTE LTD
    Inventors: Yong Zhang, Chih-Yu Chao
  • Patent number: 10513738
    Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 24, 2019
    Assignee: North Carolina State University
    Inventor: Matthew Breen
  • Patent number: 10501806
    Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 10, 2019
    Assignee: North Carolina State University
    Inventor: Matthew Breen